Skip to main content
. 2023 Oct 7;44(44):4622–4633. doi: 10.1093/eurheartj/ehad637

Figure 2.

Figure 2

EXPLORER-HCM study design. Patients with baseline left ventricular outflow tract pressure gradient >50 mmHg and New York Heart Association Classes II and III symptoms were randomized 1:1 to receive once-daily oral mavacamten (starting dose of 5 mg with a two-step dose titration) or placebo for 30 weeks. Adapted from Ho et al.35 with permission from Wolters Kluwer Health, Inc.